11.70Open11.70Pre Close0 Volume0 Open Interest22.50Strike Price0.00Turnover306.09%IV-21.21%PremiumNov 15, 2024Expiry Date13.59Intrinsic Value100Multiplier9DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9515Delta0.0246Gamma0.65Leverage Ratio-0.0201Theta-0.0034Rho-0.62Eff Leverage0.0014Vega
Biomea Fusion Stock Discussion
Biomea Fusion Inc - Preclinical Data Shows Bmf-219 Enhanced Effectiveness of GLP-1-Based Therapies
REDWOOD CITY, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers, today reported third quarter 2024 financial results and corporate hig...
trigger sold 1/4 during while market shaky
hope the diabetes study outcome rocket
No comment yet